Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
UroGen Pharma develops innovative, proprietary drug delivery solutions for uro-oncology and urological cancers. Its core technology, RTGel, enables sustained, targeted release of existing and investigational drugs like mitomycin, aiming to improve efficacy and reduce invasiveness of treatments for conditions such as UTUC and bladder cancer. The company focuses on minimally invasive therapies, leveraging its strong IP portfolio and regulatory expertise to address unmet medical needs in the urinary tract.
This description was generated via AI from an annual report. Updated about 1 year ago.